Investigators also glance to evaluate linvoseltamab in relapsed/refractory a number of myeloma as part of the stage 3 LINKER-MM3 trial. Experimental: Dose expansion_sub-population 2_higher dose of niraparib MTDs and/or candidate RP2Ds for elimusertib utilized in combination with niraparib at an increased preset dose. The drug inhibits the growth of tumor https://risdiplam21098.blogunteer.com/26357539/the-best-side-of-abemaciclib